{"filings":[{"id":2474722,"accession_number":"0001193125-26-365556","cik":2100782,"company_name":"Generate Biomedicines, Inc.","ticker":"GENB","form_type":"8-K","filed_at":"2026-08-25T23:28:57+00:00","items":["7.01","9.01"],"status":"ready","headline":"Generate:Biomedicines reveals GB-0895 data: ~98-day half-life, 6-month biomarker control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 (GB-0895-101): single 300 mg SC cuts BEC, FeNO, IL-5, IL-13 in mild-moderate asthma for ≥6 months; ~98-day half-life.","COPD Part C (N=40): biomarker reductions from Month 1 sustained ≥6 months; 300 mg comparable to 600 mg; no related SAEs.","Phase 3 trials SOLAIRIA-1 (NCT07276724) & SOLAIRIA-2 (NCT07359846) each N=786, severe uncontrolled asthma; primary endpoint AAER at 52 weeks.","GB-0895 well-tolerated: majority of TEAEs mild-moderate; all ISRs Grade 1; no anti-drug antibody impact on half-life."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1693422792.8999999,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2087651,"accession_number":"0001193125-26-336462","cik":2100782,"company_name":"Generate Biomedicines, Inc.","ticker":"GENB","form_type":"8-K","filed_at":"2026-08-06T10:00:47+00:00","items":["2.02","9.01"],"status":"ready","headline":"Generate Biomedicines Q2 net loss $67.3M; Phase 3 asthma studies advancing, cash $457.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.3M (down from $10.1M YoY); net loss $67.3M vs $56.7M YoY; cash $457.4M (down from $516.6M Q1).","Phase 3 SOLAIRIA-1/2 for GB-0895 (anti-TSLP) in severe asthma recruiting in 33 countries; Phase 1b COPD data at ERS Sept 8.","Phase 1 for GB-4362 (MMAE neutralizer) dosed first cohort; FDA Fast Track for urothelial cancer toxicity reduction.","Novartis advanced a biologic designed with Generate's platform into preclinical pipeline; first AI-enabled biologic to reach this stage.","GB-5267 CAR T Phase 1 recruiting for ovarian cancer; first patient expected in 2026; cash runway into H1 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":13538000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1693422792.8999999,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97710,"accession_number":"0001193125-26-209899","cik":2100782,"company_name":"Generate Biomedicines, Inc.","ticker":"GENB","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Generate Q1 net loss widens to $61.7M, cash $516.6M post-IPO; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $61.7M vs $44.3M YoY; revenue $7.2M (down 18% from $8.8M).","Cash & equivalents $516.6M, includes $369.3M IPO proceeds; runway into H1 2028.","GB-0895 (anti-TSLP) Phase 3 SOLAIRIA-1/2 ongoing in severe asthma; Phase 1b in COPD.","GB-4362 (MMAE neutralizer) FDA Fast Track; first patient dosing expected mid-2026.","GB-5267 (MUC16 armored CAR T with Roswell Park) first patient expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":7224000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1693422792.8999999,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112820,"accession_number":"0001193125-26-085780","cik":2100782,"company_name":"Generate Biomedicines, Inc.","ticker":"GENB","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Generate Biomedicines adopts amended charter and bylaws for public company governance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended charter authorizes 500M common shares and 10M undesignated preferred shares.","Stockholder actions by written consent and ability to call special meetings eliminated.","Bylaws establish advance notice procedures for stockholder proposals and director nominations.","Changes previously disclosed in S-1 registration statement; effective upon IPO completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1693422792.8999999,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}